Rifapentine

MAGNETIC RESONANCE IMAGING The importance of MRI continues to increase We continue to profit from our own pioneering work in the area of magnetic resonance imaging. Magnevist was not only the world's first contrast medium for magnetic resonance imaging, but it continues to be the leading product worldwide in this area. In addition, we are benefiting from a drastic increase in the number of innovative procedures such as magnetic resonance imaging. MRI is becoming increasingly important as a stateof-the-art technology for monitoring the success of a therapy. The importance of magnetic resonance imaging for the medical field was acknowledged at the end of 2003, when the Nobel Prize in Medicine was awarded to Paul C. Lauterbur and Sir Peter Mansfield. The two scientists laid the essential foundations for the medical use of MRI, thereby enabling the broad use of this diagnostic technology.

Given the cross-resistance between rifapentine and other rifamycin derivatives, the advantage of rifapentine over rifampin lies its pharmokinetic properties.
45 injection , dihydroergotamine injection , dihydroergotamine nasal spray , dolophine , dolophine oral , dolophine oral solution , ercaf , ergo-caff , ergomar , ergotamine and caffeine rectal suppositories , ergotamine sublingual tablets , ergotamine tartrate and caffeine , ezetimibe and simvastatin , folergot-df , garlic , gengraf , gengraf solution , halcion , hardhay , hypericum , hypericum perforatum , indinavir , klamath weed , lipitor , lovastatin , lovastatin extended release , lunelle , medroxyprogesterone acetate and estradiol cypionate injection , methadone diskets , methadone dispersible , methadone hydrochloride injection , methadone injection , methadone oral , methadone oral solution , methadose , mevacor , midazolam injection , midazolam syrup , migergot , migranal , millepertuis , mycobutin , neoral , neoral injection , neoral solution , niacin extended-release and lovastatin , niravam , phenerbel-s , priftin , propulsid , propulsid suspension , restasis , rifabutin , rifadin , rifadin injection , rifampin , rifampin injection , rifapentine , rimactane , rosin rose , rustic treacle , sandimmune , sandimmune injection , sandimmune solution , simvastatin , sjw , spastrin , st.

Site map contact advanced search home news treatment & care hiv worldwide living with hiv preventing hiv organisations hiv basics about us treatment & care espaol franais portugus p other drugs aciclovir zovirax ; adefovir dipivoxil hepsera ; albendazole zentel ; alcohol alefacept amikacin amikin ; amitriptyline hydrochloride amphotericin ampicillin penbritin ; anabolic steroids aspirin atorvastatin lipitor ; atovaquone wellvone ; autologous cd8 t-cell infusion azithromycin zithromax ; bleomycin buprenorphine butrans temgesic transtec ; bupropion zyban ; cannabis capreomycin capastat ; capsaicin axsain zacin ; carbamazepine carnitine carnitor ; caspofungin cancidas ; chloroquine avloclor malarivon nivaquine ; chop ciclosporin neoral sandimmun ; cidofovir vistide ; ciprofloxacin ciproxin ciloxan ; clarithromycin clarosip klaricid klaricid xl ; clindamycin dalacin c ; clofazimine clotrimazole canesten ; cocaine codeine phosphate comp corticosteroids co-trimoxazole septrin ; cyclophosphamide endoxana ; cycloserine cytarabine dacarbazine dtic-dome ; dapsone daunorubicin diamorphine hydrochloride heroin ; diclofenac voltarol diclomax motifene ; dihydrocodeine tartrate dihydroepiandrosterone dhea ; doxorubicin hydrochloride caelyx ; echinacea ecstasy entecavir baraclude ; epoetin alfa and beta erythromycin erymax erythrocin erythroped erythroped a ; ethambutol hydrochloride etoposide etopophos vepesid ; ezetimibe ezetrol ; famciclovir famvir ; fenofibrate lipantil supralip 160 ; fluconazole diflucan ; flucytosine ancotil ; fluorouracil fluoxetine prozac ; folate folinic acid fomivirsen foscarnet sodium foscavir ; gabapentin neurontin ; gamma-hydroxybutyrate ganciclovir cymevene ; garlic gentamicin cidomycin genticin ; glutamine hormonal contraceptives human growth hormone hypericin st johns wort ; ibuprofen imatinib glivec ; imiquimod aldara ; interferon alfa interferon beta avonex rebi betaferon ; interleukin-2 proleukin ; irinotecan hydrochloride campto ; iron isoniazid itraconazole sporanox ; ketamine ketalar ; ketoconazole nizoral ; lomustine loperamide hydrochloride imodium ; mbacod megestrol acetate megace ; metformin hydrochoride glucophage glucophage sr ; methadone hydrochloride methadose ; methamphetamine methotrexate methylphenidate hydrochloride ritalin concerta xl equasym xl ; metronidazole flagyl flagyl s metrolyl ; mexiletine hydrochloride mexitil ; mitozantrone novantrone onkotrone ; mopp morphine oramorph sevredol morcap sr morphegesic sr mst continus mxl zomorph ; n-acetyl cysteine nac ; naltrexone hydrochloride nalorex ; nimodipine nimotop ; nystatin nystan nystaform tinaderm-m ; octreotide sandostatin ; ofloxacin tarivid ; omeprazole losec ; otc paclitaxel taxol ; paracetamol paromomycin pentamidine isetionate pentacarinat ; peptide t pioglitazone actos ; phenytoin epanutin ; posaconazole pravastatin sodium lipostat ; pregabalin lyrica ; primaquine procaine hydrochloride procarbazine pro-mace mopp pyrazinamide pyrimethamine daraprim ; ranitidine zantac ; reticulose retinoic acid ribavirin copegus rebetol virazole ; rifabutin mycobutin ; rifampicin rifadin rimactane ; rifapentine rituximab mabthera ; rosiglitazone avandia ; rosuvastatin crestor ; selenium sildenafil viagra ; simvastatin zocor ; streptomycin sulfadiazine tadalafil cialis ; tea tree oil thalidomide total parenteral nutrition tramadol hydrochloride trimethoprim monotrim ; trimetrexate valaciclovir valtrex ; valganciclovir valcyte ; valproic acid depakote ; vardenafil levitra ; vinblastine sulphate velbe ; vincristine sulphate oncovin ; vitamin a vitamin b1 vitamin b12 vitamin b2 vitamin b6 vitamin c vitamin d vitamin e voriconazole vfend ; zinc support our work today you are here home treatment & care treatment & care a to z drugs other drugs bleomycin printer-friendly version send to a friend glossary comment bleomycin is an approved anti-cancer drug which appears to work by fragmenting dna.

The main goal of all support groups for rare chromosome disorders is to support people with a rare chromosome disorder and their families. Support groups often mention as a sub goal: meeting other parents and families and exchange of information. The physicians interviewed underscore the importance of special support for these people. Partners in this study, who are not especially focused on rare chromosome disorders, but more generally on rare diseases, do have similar objectives: support for patients with a rare disease. The Dutch Steering Committee for Orphan Drugs, the Dutch Working Group for Rare Diseases, VSOP16 and Eurordis pay also attention to lobbying activities, e.g. in the field of orphan drugs. Most networks for rare chromosome disorders and all professionally organisations mentioned stimulation of research as an additional goal, except for Leona eV Germany ; . The support function of the organisations is carried out through finding and exchanging information on rare disorders. UniqueDanmark mentioned that there is little support from geneticist in Denmark and that no clinical expert centre will be established for very rare chromosome disorders in the near future. Almost all organisations interviewed are set up for rare diseases or, more specifically, rare chromosome disorders. The only exception is FVO The Netherlands ; , which strives at improvement of daily life for people with an intellectual disability in general. Yet the syndrome networks of FVO are especially established for rare disorders. Most partners focus on activities in their native country, except for Unique UK, the European Chromosome 11q Network, Ring 14, and Eurordis, which have a European or international focus. Almost all partners mentioned that they are interested in European international cooperation on rare diseases and rare chromosome disorders. FVO has many international contacts in the field of intellectual disability, yet few on rare chromosome disorders. The reason is that the priority of FVO goes to the disability in general, not to rare disorders. Conclusions: Although formulated slightly different the main goal of support groups is support persons with rare chromosome ; disorders and their families. There is strong recognition of the need for meetings, exchange of information and cooperation. Most organisations also aim at stimulation of research, although this is more clear for medical professionals. Leona eV is the only partner that does not show interest in research as objective. Recommendations Support groups for rare diseases and disorders have common goals. Due to the fact that they are concerned with rare disorders, they should consider more cooperation, both on national as well as international level. A good example of cooperation was the joint poster at the Conference on Rare Disorders and Diseases in Paris, 16 an 17 October 2003. ; 1.3 Activities and ritonavir. PHARMACOKINETICS OF RIFAPENTINE IN CHILDREN. M. J. Blake, PhD, MD, S. M. Abdel-Rahman, PharmD, R. F. Jacobs, MD, N. K. Lowery, RN, G. L. Kearns, PharmD, PhD, Children's Mercy Hospitals and Clinics, Univ of Arkansas Med Cntr & Arkansas Children's Hospital Research Institute and Medical Center, Kansas City, MO. Rifapentine RIF ; is a rifamycin antibiotic approved for the treatment of pulmonary infections caused by M. tuberculosis that has potential therapeutic advantages over existing rifamycins. This study was designed to characterize the pharmacokinetics of RIF in children. METHODS: 24 children 7.1 3.3 yr; 27.9 11.9 kg ; were enrolled in this open label study. Children received a single oral dose of RIF 150 or 300 mg ; followed by repeated blood sampling n 11 ; over 32 hr and quantitation of RIF and 25-desacetyl rifapentine DRF ; by HPLC. Pharmacokinetic parameters were determined using a model independent approach. RESULTS: Due to a large degree of intersubject variability, no relationship was observed between weight-normalized dose and exposure. A weak, albeit significant, relationship was observed between age and dose-normalized AUC0-n and AUC0- r2 0.22, p 0.02 ; . Similarly, age appeared to account, in part, for the extent of DRF formation r2 0.27, p 0.01 ; . In contrast, no correlation was observed between age and dose-normalized Cmax or Vd F. Adverse events related to the administration of RIF were mild and included stomach ache n 1 ; and vomiting n 2 ; . CONCLUSIONS: RIF appears to be well tolerated in children 212 yr. Given a comparable weight normalized dose, RIF exposure estimates are slightly lower in children than reported for adults. However, putative pharmacodynamic targets for highly susceptible isolates appear to be achieved in the majority of children receiving a RIF dose of 510 mg kg. Following oral administration of a single 600 mg dose to healthy adult volunteers, the relative bioavailability using an oral solution as a reference ; was 70%; the absolute bioavailability of rifapentine has not been determined and rituxan. On lipid biosynthesis in isolated rat hepatocytes. J. Nutr. 120: 668-673. Kay, R. M. 1982 ; Dietary fiber. J. Lipid Res. 23: 221-242. Story, J. A. 1980 ; The role of dietary fiber in lipid metabolism. Adv. Lipid Res. 18: 229-246. Story, J. A. 1986 ; Modification of steroid excretion in response to dietary fiber. In: Dietary Fiber, Basic and Clinical Aspects Vahouny, G. V. &. Kritchevsky, D., eds. ; , pp. 253-264. Plenum Press, New York, NY. Chen, W. J. & Anderson, J. W. 1984 ; Propionate may mediate the hypocholesterolemic effects of certain soluble plant fibers in cholesterol-fed rats. Proc. Soc. Exp. Biol. Med. 175: 215-218. Folch, J., Lees, M. & Sloanestanley, G. H. 1957 ; A simple method for isolation and purification of total lipids from animal tissue. J. Biol. Chem. 226: 497-509. Seary, R. L. &. Bergquist, L. M. 1960 ; A new color reaction for the quantitation of serum cholesterol. Clin. Chim. Acta 5: 192-199. Reynolds, P. J., Huntington, G. B. &. Reynolds, C. K. 1986 ; Determination of volatile fatty acids, lclate, and betahydroxybutyrate in blood by ion exchange cleanup and gas chromatography. J. Arum Sci. 63: 424A. Vahouny, G. V., Khalafi, R., Satchithanandam, S., Watkins, D. W., Story, J. A., Cassidy, M. M. &. Kritchevsky, D. 1987 ; Dietary fiber supplementation and fecal bile acids, neutral steroids and divalent cations in rats. J. Nutr. 117: 2009-2015. SAS Institute Inc. 1985 ; SAS User's Guide: Basics, Version 5.

This study was designed to describe the population pharmacokinetics of rifapentine RFP ; and 25-desacetyl RFP in a South African pulmonary tuberculosis patient population. Special reference was made to studying the influence of previous exposure to rifampin RIF ; and the variability in pharmacokinetic parameters between patients and between occasions and the influence of different covariates. Patients were included in the study if they had been receiving first-line antimycobacterial therapy rifampin, isoniazid, pyrazinamide, and ethambutol ; for not less than 4 weeks and not more than 6 weeks and were divided into three RFP dosage groups based on weight: 600 mg, 45 kg; 750 mg, 46 to 55 kg; and 900 mg, 55 kg. Participants received a single oral dose of RFP together with concomitant antimycobacterial agents, excluding RIF, on study days 1 and 5 after they ingested a soup-based meal. The RFP and 25-desacetyl RFP concentration-time data were analyzed by nonlinear mixed-effect modeling using NONMEM. The pharmacokinetics of the parent drug were modeled separately, and the individual pharmacokinetic parameters were used as inputs for the 25-desacetyl RFP pharmacokinetic model. A one-compartment disposition model was found to best describe the data for both the parent and the metabolite, and the metabolite was assumed to be formed only from the central compartment of the parent drug. Prior treatment with RIF did not alter the pharmacokinetics of RFP but appeared to increase the excretion of 25-desacetyl RFP in a nonlinear fashion. The RFP oral clearance and volume of distribution were found to increase by 0.049 liter h and 0.691 liter, respectively, with a 1-kg increase from the median weight of 50 kg. The oral clearance of 25-desacetyl RFP was found to be 35% lower in female patients. The model developed here describes the population pharmacokinetics of RFP and its primary metabolite in tuberculosis patients and includes the effects of prior administration with RIF and covariate factors. Rifapentine RFP ; is a member of the rifamycin family and is currently registered in the United States for the treatment of tuberculosis in human immunodeficiency virus HIV ; -negative patients with noncavitary tuberculosis TB ; and with a sputum sample which is negative for acid-fast bacilli by smear at 2 months of therapy 2 ; . Treatment guidelines recommend dosing RFP 600 mg orally ; together with the companion firstline antimycobacterial drug isoniazid INH ; once weekly, following the first 8 weeks of treatment with rifampin RIF ; , INH, pyrazinamide PZA ; , and ethambutol EMB ; , to complete 6 months of therapy. The primary metabolic pathways for RFP are deacetylation and nonenzymatic hydrolysis. This results in one primary enzymatic metabolite, 25-desacetyl RFP, and two secondary nonenzymatic metabolites, 3-formyl RFP and 3-formyldesacetyl RFP 18 ; . The primary route of elimination for the rifamycins is via biliary excretion with enterohepatic recirculation, although gastrointestinal secretion and renal clearance also play a role 1, 4, 18 ; . RFP is an inducer of cytochrome P450 CYP ; 3A4 and CYP2C8 9 at the same order of magnitude as RIF 1, 3, 8 ; , although it does not possess the same autoinductive properties 10, 11 ; . The pharmacokinetics of RFP in TB patients have been described previously by using noncompartmental techniques 16, 21 ; . The effects of age 14 ; , sex 13 ; , various degrees of hepatic dysfunction 15 ; , and HIV infection 12 ; on the pharmacokinetics of RFP have all been investigated in separate studies. The data from those studies were all analyzed by model-independent methods, and only a single covariate factor at a time was investigated. Furthermore, the impact of prior administration of RIF on the pharmacokinetics of RFP has not been investigated in patients. This study was designed to describe the population pharmacokinetics of RFP and 25-desacetyl RFP in a South African pulmonary TB patient population receiving companion frontline antimycobacterial agents concomitantly. Special reference was made to investigating the influence of previous exposure to RIF and the variability in the pharmacokinetic parameters between patients and between occasions and the influence of different covariates on RFP and 25-desacetyl RFP pharmacokinetics and rms. 11. Glvez, J., Garca-Domenech, R., de Julin-Ortiz, J. V. et al. 1994 ; . Topological approach to analgesia. Journal of Chemical Information and Computer Sciences 34, 1198203. 12. Ros-Santamarina, I., Garca-Domenech, R., Glvez, J. et al. 1998 ; . New bronchodilators selected by molecular topology. Bioorganic and Medicinal Chemistry Letters 8, 47782. 13. Casabn, E., Antn-Fos, G. M., Glvez, J. et al. 1999 ; . Search of new antihistaminic compounds by molecular connectivity. Quantitative Structure-Activity Relationships 18, 3542. 14. de Julin-Ortiz, J. V., Glvez, J., Muoz-Collado, C. et al. 1999 ; . Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds. Journal of Medicinal Chemistry 42, 330814. 15. de Gregorio-Alapont, C., Garca-Domenech, R., Glvez, J. et al. 2000 ; . Molecular topology: a useful tool for the search of new antibacterials. Bioorganic and Medicinal Chemistry Letters 10, 20336. 16. Garca-Domenech, R., Catal, A. I., Garca-Garca, A. et al. 2002 ; . QSAR by molecular topology of 2, 4-dihydroxythiobenzanilides: a virtual screening approach to optimize the antifungal activity. Indian Journal of Chemistry 41B, 237684. 17. Gozalbes, R., Brun-Pascaud, M., Garca-Domenech, R. et al. 2000 ; . Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening. Antimicrobial Agents and Chemotherapy 44, 276470. 18. Burke, A. & Cunha, M. D. 1988 ; . Aminoglucsidos: papel actual en la terapia antimicrobiana. Pharmacotherapy 8, Suppl. 6, 33450. 19. Fernandes, P. B., Hardy, D. J., McDaniel, D. et al. 1989 ; . In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrobial Agents and Chemotherapy 33, Suppl. 9, 15314. 20. Perronne, C., Gikas, A., Truffot-Pernot, C. et al. 1991 ; . Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of M. avium complex within human macrophages. Antimicrobial Agents and Chemotherapy 35, 13569. 21. Jacobs, M. R. 1995 ; . Activity of quinolones against mycobacteria. Drugs 49, Suppl. 2, 6775. 22. Garca-Snchez, J. E., Lpez, R. & Prieto, J. 1999 ; . Antimicrobianos en medicina, pp. 44955. Sociedad Espaola de Quimioterapia. Prous Science, S.A. 23. Gillespie, S. H. & Billington, O. 1999 ; . Activity of moxifloxacin against mycobacteria. Journal of Antimicrobial Chemotherapy 44, 3935. 24. Glvez, J., Garca-Domenech, R., de Julin-Ortiz, J. V. et al. 1995 ; . Topological approach to drug design. Journal of Chemical Information and Computer Sciences 35, 27284. 25. Glvez, J., Garca-Domenech, R., Salabert, M. T. et al. 1994 ; . Charge indices. New topological descriptors. Journal of Chemical Information and Computer Sciences 34, 5205. 26. Glvez, J., Garca-Domenech, R., de Gregorio-Alapont, C. et al. 1996 ; . Pharmacological distribution diagrams: a tool for the new drug design. Journal of Molecular Graphics and Modelling 14, 2726. 27. Furnival, G. M. & Wilson, R. W. 1974 ; . Regressions by leaps and bounds. Technometrics 16, 499511. 28. Hocking, R. R. 1972 ; . Criteria for selection of a subset regression: which one should be used? Technometrics 14, Suppl. 4, 96770. 29. Allen, D. M. 1974 ; . The relationship between variable selection and data augmentation and a method for prediction. Technometrics 16, 1257. 30. Wold, S. & Eriksson, L. 1995 ; . Statistical validation of QSAR results. In Chemometric Methods in Molecular Design Van de Waterbeemd, H., Ed ; , vol. 2, pp. 30918. VCH, New York. 31. Heifets, L. 1996 ; . Susceptibility testing of Mycobacterium avium complex isolates. Antimicrobial Agents and Chemotherapy 40, 175967. 32. Franzblau, S. G., Witzig, R. S., McLaughlin, J. C. et al. 1998 ; . Rapid low technology MIC determination with clinical Mycobacterium isolates by using the microplate alamar blue assay. Journal of Clinical Microbiology 36, 3626. 33. Heifets, L. B. 1996 ; . Clinical mycobacteriology. Drug susceptibility testing. Clinics in Laboratory Medicine 16, Suppl. 3, 64156. 34. Rikimaru, T., Kondo, M., Kondo, S. et al. 2000 ; . Efficacy of common antiseptics against mycobacteria. International Journal of Tuberculosis and Lung Disease 4, 5706. 35. Donald, P. R., Sirget, F. A., Kanyok, T. P. et al. 2000 ; . Early bactericidal activity of paromomycin aminosidine ; in patients with smearpositive pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy 44, Suppl. 12, 32857. 36. Gadre, D. V. & Talwar, V. 1999 ; . In vitro susceptibility testing of Mycobacterium tuberculosis strains to trifluoperazine. Journal of Chemotherapy 11, Suppl. 3, 2036. 37. Zhang, Y., Permar, S. & Sun, Z. 2002 ; . Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. Journal of Medical Microbiology 51, Suppl. 1, 429 and rifapentine.
Site map contact advanced search home news treatment & care hiv worldwide living with hiv preventing hiv organisations hiv basics about us treatment & care espaol franais portugus p other drugs aciclovir zovirax ; adefovir dipivoxil hepsera ; albendazole zentel ; alcohol alefacept amikacin amikin ; amitriptyline hydrochloride amphotericin ampicillin penbritin ; anabolic steroids aspirin atorvastatin lipitor ; atovaquone wellvone ; autologous cd8 t-cell infusion azithromycin zithromax ; bleomycin buprenorphine butrans temgesic transtec ; bupropion zyban ; cannabis capreomycin capastat ; capsaicin axsain zacin ; carbamazepine carnitine carnitor ; caspofungin cancidas ; chloroquine avloclor malarivon nivaquine ; chop ciclosporin neoral sandimmun ; cidofovir vistide ; ciprofloxacin ciproxin ciloxan ; clarithromycin clarosip klaricid klaricid xl ; clindamycin dalacin c ; clofazimine clotrimazole canesten ; cocaine codeine phosphate comp corticosteroids co-trimoxazole septrin ; cyclophosphamide endoxana ; cycloserine cytarabine dacarbazine dtic-dome ; dapsone daunorubicin diamorphine hydrochloride heroin ; diclofenac voltarol diclomax motifene ; dihydrocodeine tartrate dihydroepiandrosterone dhea ; doxorubicin hydrochloride caelyx ; echinacea ecstasy entecavir baraclude ; epoetin alfa and beta erythromycin erymax erythrocin erythroped erythroped a ; ethambutol hydrochloride etoposide etopophos vepesid ; ezetimibe ezetrol ; famciclovir famvir ; fenofibrate lipantil supralip 160 ; fluconazole diflucan ; flucytosine ancotil ; fluorouracil fluoxetine prozac ; folate folinic acid fomivirsen foscarnet sodium foscavir ; gabapentin neurontin ; gamma-hydroxybutyrate ganciclovir cymevene ; garlic gentamicin cidomycin genticin ; glutamine hormonal contraceptives human growth hormone hypericin st johns wort ; ibuprofen imatinib glivec ; imiquimod aldara ; interferon alfa interferon beta avonex rebi betaferon ; interleukin-2 proleukin ; irinotecan hydrochloride campto ; iron isoniazid itraconazole sporanox ; ketamine ketalar ; ketoconazole nizoral ; lomustine loperamide hydrochloride imodium ; mbacod megestrol acetate megace ; metformin hydrochoride glucophage glucophage sr ; methadone hydrochloride methadose ; methamphetamine methotrexate methylphenidate hydrochloride ritalin concerta xl equasym xl ; metronidazole flagyl flagyl s metrolyl ; mexiletine hydrochloride mexitil ; mitozantrone novantrone onkotrone ; mopp morphine oramorph sevredol morcap sr morphegesic sr mst continus mxl zomorph ; n-acetyl cysteine nac ; naltrexone hydrochloride nalorex ; nimodipine nimotop ; nystatin nystan nystaform tinaderm-m ; octreotide sandostatin ; ofloxacin tarivid ; omeprazole losec ; otc paclitaxel taxol ; paracetamol paromomycin pentamidine isetionate pentacarinat ; peptide t pioglitazone actos ; phenytoin epanutin ; posaconazole pravastatin sodium lipostat ; pregabalin lyrica ; primaquine procaine hydrochloride procarbazine pro-mace mopp pyrazinamide pyrimethamine daraprim ; ranitidine zantac ; reticulose retinoic acid ribavirin copegus rebetol virazole ; rifabutin mycobutin ; rifampicin rifadin rimactane ; rifapentine rituximab mabthera ; rosiglitazone avandia ; rosuvastatin crestor ; selenium sildenafil viagra ; simvastatin zocor ; streptomycin sulfadiazine tadalafil cialis ; tea tree oil thalidomide total parenteral nutrition tramadol hydrochloride trimethoprim monotrim ; trimetrexate valaciclovir valtrex ; valganciclovir valcyte ; valproic acid depakote ; vardenafil levitra ; vinblastine sulphate velbe ; vincristine sulphate oncovin ; vitamin a vitamin b1 vitamin b12 vitamin b2 vitamin b6 vitamin c vitamin d vitamin e voriconazole vfend ; zinc support our work today you are here home treatment & care treatment & care a to z drugs other drugs entecavir baraclude ; printer-friendly version send to a friend glossary comment entecavir is a nucleoside analogue drug a guanosine analogue ; used as an antiviral treatment for hepatitis as entecavir was originally thought to have selective activity against hepatitis b virus hbv ; polymerase only, it has been the recommended therapy for hbv treatment in people with hiv-hbv coinfection and robaxin. Thm Effect of PS-K on the CarcinageneIs of the Submandibular Glankd of Rat. Y.W. Palk * mim ILK. Owc Dept. Oral Pathology. College of Dentistry, Kyunghee Unversity, Seoul, Korea.

26 November, 1995, Kyoto, Japan. 39. Vaginosonography & Fallopian Tubes Author ; 32nd Research Meeting of MRC Bombay Hospital, 11th December, 1995, Bombay. 32nd Research Meeting of MRC Bombay Hospital, 11th December 1995, Bombay. 32nd Research Meeting of MRC Bombay Hospital, 11th December 1995, Bombay. 48th Research Meeting of MRC Bombay Hospital, 14th July, 1997 48th Research Meeting of MRC Bombay Hospital, 14th July, 1997 7th National Conference on Ultrasound, 27-28 February & 1st March 1998, The Leela, Bombay, India International Congress on Fallopian Tubes, 5-8 February, 1998, Bombay Hospital, Bombay, India 26th Annual BOGS Conference on 27-28 March, 1998, Oberoi Towers, Bombay, India XVI AOCOG, Palace of Golden Horses, 14-19 June, 1998 Kuala Lumpur, Malaysia 42nd All India Obstetric & Gynaecological Congress, 27-30 December, 1998, Hyderabad. The First Congress on Controversies in Obstetrics, Gynaecology & Infertility, October28-31, 1999, Prague, Czech Republic Global Congress on Gynecologic Endoscopy, ART & Infertility, 6-9 December 2001, Goa-India. 46th AICOG, January 6-9, 2003 Bangalore Palace Grounds, Bangalore and rocephin.